Skip to content

Ridge Preservation With Moldable Beta-tricalcium Phosphate Bone Substitute on Non-containable Non-Molar Extraction Sites

Ridge Preservation With Hardening Calcium Phosphate Bone Substitutes and Resorbable Membrane for Implant Site Development on Non-containable Extraction Sites: A Clinical and Histological Prospective Case Series in Humans

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03215667
Enrollment
9
Registered
2017-07-12
Start date
2017-08-01
Completion date
2019-11-03
Last updated
2021-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alveolar Ridge Preservation, Dental Implants

Brief summary

Purpose of the single arm study is to clinically and histologically evaluate alloplastic in-situ hardening, moldable beta-tricalcium phosphate(TCP) bone graft material and polylactide membrane in alveolar ridge preservation following extraction of non-molar teeth with non-containable extraction sockets.

Interventions

easy-graft will be grafted to a single extraction socket and covered by polylactide membrane to facilitate regeneration of new bone in order to preserve alveolar ridge dimensions.

Sponsors

Sunstar Americas
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* adequate restorative space for a dental implant restoration, if the subject decides previous to study participation that they would like an implant. Note, agreement to implant placement is not a requirement of the study * minimum of 10-mm vertical bone without impinging on adjacent vital structures (Maxillary sinus, neurovascular bundles) * single-rooted tooth to be extracted * American Society of Anesthesiologists (ASA) Physical Status Classification I or II * age \>18 years old * subjects who had \>50% of height on any portion on the buccal wall of dehiscence and/or fenestration of the extraction socket following extraction will be included from this study * adjacent teeth to extraction site will be present during healing period * willingly sign informed consent and authorization.

Exclusion criteria

* do not meet any inclusion criteria * pregnancy or nursing woman * subjects with active systemic or localized infection (exclude chronic periodontitis) * subjects with a history of any medical conditions that contraindicated or weighed against dental implant placement such as history of bisphosphonate drug use, chemotherapeutic or immunosuppressive agents, autoimmune disease, or poorly controlled diabetes (HBA1c\>7%) * subjects with smoking habit (more than 10 cigarettes per day)

Design outcomes

Primary

MeasureTime frameDescription
Change in Radiographic Measurements of Bone Ridge DimensionsChange from Baseline at 3 monthsCone-beam computed tomography (CBCT) was taken at the ridge preservation procedure (baseline) and 3 months after the procedure. The horizontal ridge width was measured at 1, 3, 5 and 7 mm below the alveolar bone crest. Overall change is the average of all measurements.

Secondary

MeasureTime frameDescription
Change in Digital Measurements of Soft Tissue DimensionsChange from baseline at 5 monthsPre- and post-surgery casts were made from impressions and scanned with a digital scanner. The soft tissue width was measured at 1, 3 and 5 mm below the ridge crest. Overall change is the average of all measurements.

Countries

United States

Participant flow

Participants by arm

ArmCount
Device Treatment
easy-graft CLASSIC (beta-Tricalcium Phosphate) grafting covered with polylactide membrane easy-graft CLASSIC (beta-Tricalcium Phosphate): easy-graft will be grafted to a single extraction socket and covered by polylactide membrane to facilitate regeneration of new bone in order to preserve alveolar ridge dimensions.
9
Total9

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyPhysician Decision4

Baseline characteristics

CharacteristicDevice Treatment
Age, Continuous58.6 years
STANDARD_DEVIATION 15.3
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
9 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
2 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
7 Participants
Sex: Female, Male
Female
6 Participants
Sex: Female, Male
Male
3 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 9
other
Total, other adverse events
0 / 9
serious
Total, serious adverse events
0 / 9

Outcome results

Primary

Change in Radiographic Measurements of Bone Ridge Dimensions

Cone-beam computed tomography (CBCT) was taken at the ridge preservation procedure (baseline) and 3 months after the procedure. The horizontal ridge width was measured at 1, 3, 5 and 7 mm below the alveolar bone crest. Overall change is the average of all measurements.

Time frame: Change from Baseline at 3 months

ArmMeasureGroupValue (MEAN)Dispersion
Device TreatmentChange in Radiographic Measurements of Bone Ridge DimensionsOverall1.59 mmStandard Deviation 1.05
Device TreatmentChange in Radiographic Measurements of Bone Ridge Dimensions1 mm below the alveolar bone crest1.89 mmStandard Deviation 1.03
Secondary

Change in Digital Measurements of Soft Tissue Dimensions

Pre- and post-surgery casts were made from impressions and scanned with a digital scanner. The soft tissue width was measured at 1, 3 and 5 mm below the ridge crest. Overall change is the average of all measurements.

Time frame: Change from baseline at 5 months

ArmMeasureGroupValue (MEAN)Dispersion
Device TreatmentChange in Digital Measurements of Soft Tissue DimensionsOverall0.99 mmStandard Deviation 2.18
Device TreatmentChange in Digital Measurements of Soft Tissue Dimensions1mm below the ridge crest2.57 mmStandard Deviation 1.35

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026